BNB Plus (BNBX) Q1 2026 earnings summary

Executive summary

• Transitioned to a digital asset treasury strategy focused on BNB, the Binance blockchain's native cryptocurrency, following a major restructuring and workforce reduction of 60% completed by December 31, 2025.

• LineaRx subsidiary continues to commercialize nucleic acid production solutions for biopharma and diagnostics, while DNA Tagging and Security Products and Services is being wound down.

Financial highlights

• Total revenues for the quarter ended December 31, 2025 were $565,394, down from $870,291 year-over-year.

• Net loss for the quarter was $18,606,182, a significant increase from a net loss of $2,668,713 in the prior year period.

• Gross profit decreased to $315,357 from $606,239 year-over-year, with gross margin dropping to 56% from 70%.

• Operating expenses surged to $19,023,638, primarily due to one-time consulting and warrant expenses related to the digital asset strategy.

• Cash and cash equivalents at quarter-end were $2,450,536, with total assets of $20,697,042.

Outlook and guidance

• Management estimates sufficient liquidity to fund operations for the next twelve months, supported by cash, cash equivalents, and liquid cryptocurrency assets.

• Digital asset and investment in digital asset trust are considered long-term holdings, not expected to be liquidated for working capital needs in the near term.